ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Blog ADC First-in-Human (FIH) Dose Selection: Designing FIH Studies for Success Optimize ADC First-in-Human Dose Selection with model-informed strategies and exposure–response insights to design safer, more…CertaraMarch 3, 2026
Start right, finish strong: Antibody-drug conjugate (ADC) studies for success On-Demand Webinar Start right, finish strong: Antibody-drug conjugate (ADC) studies for success Learn how to build regulatory-ready first-in-human (FIH) dose strategies for antibody-drug conjugates (ADCs). Discover how…CertaraFebruary 23, 2026
Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants Publication Population Pharmacokinetics of Clesrovimab in Preterm and Full-Term Infants This study, published in Clinical Pharmacology & Therapeutics (CPT), shows how population pharmacokinetic modeling supports…CertaraFebruary 2, 2026
CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access Webinar CHI ADC Webinar Series: From First-in-Human Dose Selection to Label Optimization, Commercial Expansion, and Market Access CertaraJanuary 14, 2026
Merck Advances Pediatric Oncology with Innovative ADC Modeling Case Study Merck Advances Pediatric Oncology with Innovative ADC Modeling Merck leveraged ADC modeling and pediatric ADC dose optimization to enable FDA acceptance and advance…CertaraDecember 12, 2025
QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™ Live Events QSP Workshop 2026 in Japan & Korea – Mastering Scalable AI-enabled QSP modeling software, Certara IQ™ Japan: February 26, 2026 - 1:00 - 5:00 pm | Korea: Wednesday, March 4, 2026…CertaraDecember 9, 2025
Modeling amyloid plaque turnover dynamics improves characterization of drug effects Publication Modeling amyloid plaque turnover dynamics improves characterization of drug effects Researchers modeled how amyloid plaques form and clear in Alzheimer’s disease, helping explain how treatments…CertaraNovember 26, 2025
Key Lessons & Opportunities in applying NCA and PopPK to ADCs Blog Key Lessons & Opportunities in applying NCA and PopPK to ADCs Applying NCA and PopPK to ADCs helps decode complex PK, balance DAR effects, and guide…CertaraOctober 24, 2025
Highlights from the FDA Guidance on Dosage Optimization for Therapeutic Radiopharmaceuticals Video Highlights from the FDA Guidance on Dosage Optimization for Therapeutic Radiopharmaceuticals Learn how radiopharmaceutical therapies work in oncology and how Certara supports development with modeling, simulation,…CertaraOctober 3, 2025
37th Annual Meeting of the Southern California Chapter Society of Toxicology (SCCSOT) Conference 37th Annual Meeting of the Southern California Chapter Society of Toxicology (SCCSOT) CertaraSeptember 22, 2025